JP2007262090A5 - - Google Patents

Download PDF

Info

Publication number
JP2007262090A5
JP2007262090A5 JP2007180835A JP2007180835A JP2007262090A5 JP 2007262090 A5 JP2007262090 A5 JP 2007262090A5 JP 2007180835 A JP2007180835 A JP 2007180835A JP 2007180835 A JP2007180835 A JP 2007180835A JP 2007262090 A5 JP2007262090 A5 JP 2007262090A5
Authority
JP
Japan
Prior art keywords
composition
factor
polysorbate
subcutaneously
intravenously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007180835A
Other languages
English (en)
Japanese (ja)
Other versions
JP4879104B2 (ja
JP2007262090A (ja
Filing date
Publication date
Priority claimed from US08/591,332 external-priority patent/US5770700A/en
Application filed filed Critical
Publication of JP2007262090A publication Critical patent/JP2007262090A/ja
Publication of JP2007262090A5 publication Critical patent/JP2007262090A5/ja
Application granted granted Critical
Publication of JP4879104B2 publication Critical patent/JP4879104B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007180835A 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方 Expired - Lifetime JP4879104B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/591,332 US5770700A (en) 1996-01-25 1996-01-25 Liquid factor IX formulations
US08/591,332 1996-01-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP9526917A Division JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方

Publications (3)

Publication Number Publication Date
JP2007262090A JP2007262090A (ja) 2007-10-11
JP2007262090A5 true JP2007262090A5 (https=) 2010-01-14
JP4879104B2 JP4879104B2 (ja) 2012-02-22

Family

ID=24366077

Family Applications (4)

Application Number Title Priority Date Filing Date
JP9526917A Withdrawn JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2007180835A Expired - Lifetime JP4879104B2 (ja) 1996-01-25 2007-07-10 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP9526917A Withdrawn JP2000504327A (ja) 1996-01-25 1997-01-09 高度に濃縮された、凍結乾燥された、および液体の、因子▲ｉｘ▼処方
JP2006141684A Pending JP2006257099A (ja) 1996-01-25 2006-05-22 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010106673A Withdrawn JP2010189433A (ja) 1996-01-25 2010-05-06 高度に濃縮された、凍結乾燥された、および液体の、因子ｉｘ処方

Country Status (8)

Country Link
US (1) US5770700A (https=)
EP (1) EP0876155B1 (https=)
JP (4) JP2000504327A (https=)
AT (1) ATE270557T1 (https=)
AU (1) AU726498B2 (https=)
CA (1) CA2241319A1 (https=)
DE (1) DE69729786T2 (https=)
WO (1) WO1997026909A1 (https=)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
US7112576B1 (en) 1999-12-10 2006-09-26 Regents Of The University Of Minnesota Compositions and methods for cryopreservation of peripheral blood lymphocytes
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002213441B2 (en) 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
AU2002351755A1 (en) * 2001-12-21 2003-07-15 Novo Nordisk A/S Liquid composition of modified factor vii polypeptides
EP1458408B1 (en) 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
CN1671410B (zh) 2002-06-21 2010-05-12 诺和诺德医疗保健公司 因子ⅶ多肽的稳定化固体组合物
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
AU2004222625A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) * 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
MXPA05010555A (es) 2003-04-04 2006-03-09 Genentech Inc Formulaciones de proteina y anticuerpo de alta concentracion.
RU2364609C2 (ru) 2003-05-23 2009-08-20 Ново Нордиск Хелт Кэр Аг Стабилизация белка в растворе
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1641487B1 (en) * 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
WO2005002615A1 (en) * 2003-07-01 2005-01-13 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
JP5653572B2 (ja) * 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN1917861B (zh) 2003-12-19 2012-03-21 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
EP1755652B1 (en) * 2004-03-19 2010-11-24 Baxter International Inc. Factor ixa for the treatment of bleeding disorders
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7625560B2 (en) * 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
PA8661401A1 (es) * 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
WO2007005482A1 (en) * 2005-06-30 2007-01-11 Ge Healthcare Bio-Sciences Corp. Detection method for gene expression
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US8449520B2 (en) * 2007-03-19 2013-05-28 HemCon Medical Technologies Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
CA2683317C (en) 2007-04-26 2014-12-16 Bayer Healthcare Llc Stabilization of liquid solutions of recombinant protein for frozen storage
US7879805B2 (en) * 2007-06-01 2011-02-01 Acologix, Inc. High temperature stable peptide formulation
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
BRPI0911048A2 (pt) * 2008-04-14 2015-12-29 Atrm Llc formulações líquidas tamponadas de gdf-5
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
AU2010221156A1 (en) 2009-03-06 2011-09-22 Genentech, Inc. Antibody formulation
EP2538967A1 (en) * 2010-02-24 2013-01-02 Arecor Limited Stable compositions of factor ix
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
WO2014144549A1 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
HK1220759A1 (zh) * 2013-03-15 2017-05-12 Hycor Biomedical Llc 用於进行过敏症和自身免疫性疾病的诊断测定的自动化免疫分析系统
AU2015236340B2 (en) * 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
WO2017096031A1 (en) 2015-12-03 2017-06-08 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-vegf
JP7110360B2 (ja) 2017-10-09 2022-08-01 テルモ ビーシーティー バイオテクノロジーズ，エルエルシー 凍結乾燥方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN113597532B (zh) 2019-03-14 2023-02-17 泰尔茂比司特生物技术有限公司 冻干容器填充固定装置、系统及使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3045153A1 (de) * 1980-11-29 1982-07-08 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x
US4470968A (en) * 1983-01-13 1984-09-11 Miles Laboratories, Inc. Pasteurized therapeutically active blood coagulation factor concentrates
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
IT1171737B (it) * 1983-10-10 1987-06-10 Vamatex Spa Gancio per la guida di nastri portapinze all'interno del passo di telai di tessitura e complesso di guida con esso realizzabile
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
US4952675A (en) * 1985-02-01 1990-08-28 New York University Method for purifying antihemophilic factor
US4770999A (en) * 1985-04-22 1988-09-13 Genetics Institute, Inc. High yield production of active Factor IX
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
JP2708749B2 (ja) * 1987-08-10 1998-02-04 エーザイ株式会社 修飾型ｔＰＡ含有注射用組成物
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
JP2715104B2 (ja) * 1988-08-18 1998-02-18 株式会社ミドリ十字 トロンビン乾燥製剤
DE3828009A1 (de) * 1988-08-18 1990-02-22 Wolfgang D Zapp Rahmen aus strangprofilen
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
JP2722143B2 (ja) * 1991-09-03 1998-03-04 株式会社ミドリ十字 トリプシンインヒビター含有凍結乾燥製剤
JPH05331071A (ja) * 1992-01-17 1993-12-14 Asahi Chem Ind Co Ltd カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
EP0689843B1 (en) * 1993-12-17 2003-09-10 Mochida Pharmaceutical Co., Ltd. Composition containing soluble thrombomodulins
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations

Similar Documents

Publication Publication Date Title
JP2007262090A5 (https=)
AR124140A2 (es) Formulaciones de anticuerpos
JP2010530846A5 (https=)
JP2012515184A5 (https=)
JP2007527914A5 (https=)
JP2010285439A5 (https=)
JP2005518433A5 (https=)
MX2010005676A (es) Metodo para retrasar el comienzo de esclerosis multiple clinicamente definida.
JP2008505857A5 (https=)
JP2008535819A5 (https=)
JP2010222367A5 (https=)
WO2009134057A3 (ko) 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
CO6400184A2 (es) Formulaciones galénicas de compuestos orgánicos
JP2009541409A5 (https=)
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
JP2009537554A5 (https=)
JP2013533269A5 (https=)
HRP20151091T1 (hr) UPORABA 24-norUDCA
WO2008075320A3 (en) Antilipidemic pharmaceutical compositions and process for preparation thereof
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2011055383A3 (en) Intranasal delivery to improve the performance of children suffering from dyslexia
TNSN08385A1 (en) Delayed-release glucocorticoid treatment of rheumatoid disease
JP2009516719A5 (https=)
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously